SPIRIVA RESPIMAT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SPIRIVA RESPIMAT (SPIRIVA RESPIMAT).
Long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine at M3 receptors in bronchial smooth muscle, leading to bronchodilation.
| Metabolism | Primarily non-enzymatic hydrolysis to inactive metabolites; minor CYP2D6 and CYP3A4 involvement. |
| Excretion | Renal excretion (60-70% unchanged) and biliary/fecal excretion (30-40%) after IV administration; after inhalation, most of the swallowed dose is eliminated fecally. |
| Half-life | Terminal elimination half-life of 27 hours after inhalation (range 13-50 hours), supporting once-daily dosing due to prolonged receptor binding. |
| Protein binding | ~72%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 32 L/kg (IV), indicating extensive tissue distribution; steady-state Vd ~1850 L after inhalation. |
| Bioavailability | Inhalation: ~19-22% of the emitted dose (mostly from lung deposition; oral bioavailability <5%). |
| Onset of Action | Inhalation: 30 minutes (bronchodilation); peak effect at 1.5-3 hours. |
| Duration of Action | >24 hours (bronchodilation sustained throughout the dosing interval; no evidence of tolerance). |
2 actuations (2.5 mcg tiotropium/actuation) once daily by oral inhalation.
| Dosage form | SPRAY |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use only if benefit outweighs risk; no specific dose adjustment provided. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not recommended for pediatric patients (safety and efficacy not established in children). |
| Geriatric use | No dose adjustment required based on age. Monitor for anticholinergic effects (e.g., constipation, urinary retention) in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SPIRIVA RESPIMAT (SPIRIVA RESPIMAT).
| Breastfeeding | Unknown excretion in human milk. M/P ratio not determined. Caution due to potential anticholinergic effects in infant (e.g., tachycardia, constipation, urinary retention). Decision: use only if clearly needed, considering risk-benefit. |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. No adequate human studies; risk cannot be excluded. Theoretical risk of anticholinergic effects in third trimester: decreased fetal heart rate variability, transient neonatal respiratory depression, and decreased neonatal gut motility. |
■ FDA Black Box Warning
Not for initial treatment of acute episodes of bronchospasm or for acute deterioration of COPD or asthma; may cause paradoxical bronchospasm.
| Serious Effects |
["Hypersensitivity to tiotropium or any component of the product","History of hypersensitivity to atropine or its derivatives"]
| Precautions | ["Paradoxical bronchospasm","Immediate hypersensitivity reactions","Worsening of narrow-angle glaucoma","Worsening of urinary retention","Use in patients with severe renal impairment (CrCl <30 mL/min) with caution","Not studied in patients with severe hepatic impairment"] |
Loading safety data…
| Fetal Monitoring |
| Maternal: pulmonary function tests, heart rate, signs of worsening COPD/asthma. Fetal: third-trimester ultrasound for amniotic fluid volume (anticholinergic effect), fetal heart rate monitoring if high dose or maternal comorbidity. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. No human data. Theoretical concern: anticholinergic effects may alter cervical mucus or fallopian tube motility, but clinical significance unknown. |